- Ho, Bing-Ching;
- Yu, I-Shing;
- Lu, Li-Fan;
- Rudensky, Alexander;
- Chen, Hsuan-Yu;
- Tsai, Chang-Wu;
- Chang, Yih-Leong;
- Wu, Chen-Tu;
- Chang, Luan-Yin;
- Shih, Shin-Ru;
- Lin, Shu-Wha;
- Lee, Chun-Nan;
- Yang, Pan-Chyr;
- Yu, Sung-Liang
There are no antivirals or vaccines available to treat Enterovirus 71 (EV71) infections. Although the type I interferon response, elicited upon virus infection, is critical to establishing host antiviral innate immunity, EV71 fails to induce this response efficiently. Here we provide new insights into potential anti-EV71 therapy by showing that neutralization of EV71-induced miR-146a prevents death in mice by restarting the production of type I interferon. EV71 infection upregulates miR-146a, which targets IRAK1 and TRAF6 involved in TLR signalling and type I interferon production. We further identify AP1 as being responsible for the EV71-induced expression of miR-146a. Surprisingly, knocking out miR-146a or neutralizing virus-induced miR-146a by specific antagomiR restores expressions of IRAK1 and TRAF6, augments IFNβ production, inhibits viral propagation and improves survival in the mouse model. Our results suggest that enterovirus-induced miR-146a facilitates viral pathogenesis by suppressing IFN production and provide a clue to developing preventive and therapeutic strategies for enterovirus infections.